Both treatments further normalized the down-regulation of SOD-1 in the MS, and activated the expression of HO-1 and GSTM1 in this brain area, as well as the expression of NQO1, SOD-1, and GSTM1 in the DRG of nerve-injured mice. This evidence concerns the gene SOD1 and myeloid sarcoma.